Thursday, April 15, 2010

Trading ideas for April 15, 2010

GMO


SBSA

Overnight positions charts update

$aria $arwr $ent $mni $pacr $pal $rfmd $xxia

ARIA


ENT


MNI


PACR


PAL


RFMD


XXIA


It's been a lllooooong ass while since I have done overnight positions gap up/continuation plays. Very excited to see my results. Good luck everyone!

Wednesday, April 14, 2010

Overnight positions

$aria $arwr $ent $mni $pacr $pal $rfmd $xxia
5%-10% each.


I will update Charts tonight. Great day today overall with big winners like $CHCI $XNPT...etc




Happy Trading

CHCI Wins the day

Premarket Alert:



2 hours after open:


Follow me on twitter @tradermarket247

Trading ideas for April 14, 2010

WCBO


XNPT



CHCI

Tuesday, April 13, 2010

AMD setup

CLSN update

Yesterday's alert.



Today the stock is up another 50 cents since my alert from yesterday.


Again, congrats to all share holders.

EK setup

Tues setup

DCTH's Phase III Trial Data to be Presented

NEW YORK, April 13 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq:DCTH - News), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine and a lead Principal Investigator of the Phase III trial, will present the abstract on June 5 at 3:30pm CT, during the Melanoma/Skin Cancer – Oral Abstract Session. The company expects to report top-line results from the trial later this month.

"ASCO's invitation to present at the podium represents a tremendous achievement for the clinicians leading our Phase III trial," said Eamonn P. Hobbs, Delcath's President and CEO. "The invitation illustrates the increasing interest in the Delcath PHP System™ as well as the data generated from the trial within the oncology clinician community. We look forward to Dr. Pingpank sharing this data and thank all of the patients and physicians for their involvement in this groundbreaking study."

Congrats for those who are still holding since alert.


HEPI setup



Watch it folks! I already bought some at $0.99. (Trade at your own risk)

Happy trading.

Monday, April 12, 2010

CLSN



My last Top 3 buy and hold stock of 2010 finally making a move today! $5 should be coming anytime now.

Thursday, April 8, 2010

AGM setups

Daily



Intraday


I don't use indicators very often but this one seems a bit overbought. Short on first sign of weakness with stop right above intraday highs.

Watch List April 08, 2010

Find one that you like. Sorry too busy/lazy to chart them all.

mdf cach cldx fun amd chci klic plab extr gsl srgl pby txrh rjet cytk gtn isr cers

Wednesday, April 7, 2010

AIG wins the day

April 1, 2010 (Last week) - AIG trading ideas from last week at $34.14

April 7, 2010 (Today)- at $39.69


April 8, 2010 (Tomorrow) - Prediction?? (Warning: Fake Candle/Volume for now)


Hah I sure wish, We will see!

NEP Setup

Tuesday, April 6, 2010

YRCW Setup


One follower alerted me on YRCW! Thanks!

Monday, April 5, 2010

Saturday, April 3, 2010

Interesting read on DCTH by drllee

Mr. Lee also known as "drllee" from investorvillage, is one of my admirable fundamental investor who has been tracking DCTH for 7 years now. He has been accumulating shares from 2003 and until as late as 2009 when non of the wall street people talks or even heard about DCTH. Here we are a year later the stock hits new high as of last week to $9.38.

Below are some of his thoughts regarding the recent run-up in share price of DCTH. Click here to see original post.


Hi lililarlar,

First, the short interest being quoted is for a settlement date 3/15, meaning the number of shorts is 2,711,800 on that date. We have no short interest data that tells us what the short interest is currently. Who knows? Given the recent run up in pps, a contributing factor could be short covering.

"Assuming good trial#3 result, wouldn't the current buildup on pps is factoring that already and the jump, again assuming good result, would not be as spectacular as it is supposed to be?"

Whether this current run up is "factored" into what the price will be after data release no one knows. Funny thing about the markets is the perceived value of a company/stock by investors. After data is released, if investors believe the data to be very compelling, then investors will place a certain value which will be reflected in the pps. Analysts will then justify their projections by whatever metric they each decide to use, and in this way, set a target share price. What that will be know one knows.

One thing we who have held DCTH shares for years know, is that there is underlying value to the technology. This is why a lot of us have stuck it out through thick and thin for years. Currently, the majority of investors are discovering what we already know. These late comers are now the ones who are buying the shares in a bidding frenzy, which may continue. But the point is, people are now establishing in all this buying and selling, a value that they feel better reflects what the coming results will be. Included in this it would appear that traders have established a bit of frothiness in the share price, given the daily run up without any period of consolidation. I do think we are in store for a correction to the share price as the uptrend is unsustainable in the short term. When this correction will occur, I do not know, but it should not distract us from the long term potential of the company if the yet to be released results is as good as we think they are. Further appreciation will no doubt come if the company continues to successfully execute its business strategy.

Peace,
Lee


Wish all DCTH stock holders well (including myself ofcourse).

Thursday, April 1, 2010

IMSC setup

ACLS Setup





Been teasing me FOREVER! Hopefully this time is for real.

Wednesday, March 31, 2010

Trading ideas for April 1, 2010

ISR


AIG

NCT setup

Deep in the Forrest! How I banked coins on $AEN


That's my GF in the middle. Either my GF is really short or those trees are really tall (we are still arguing...).


Solduc Water Fall!

Those tall trees blocked all kinds of wavelength such as, Cellphone signal, internet, Wifi, 3G, Microwave.. well not Microwave, FOR TWO DAYS !!!! I felt so awful not knowing what was going on with the outside world. However, I wouldn't have banked so much coin on $AEN(Bought last Friday) yesterday if it wasn't for those tall trees which forced me to swing it for two days(Sold at $2.40) straight.

CHCI setup



====================================

Another note: $DCTH New high again, Unreal move!

My top 3 buy and hold stocks for 2010. Nailed two of them, one more to go!

Tuesday, March 30, 2010

$DCTH update



Congratulations for those who followed me and bought the stock. I have been accumulating DCTH since $4's and sold some trading shares at around $8.20 today while holding my core position. DCTH will soon be releasing it's FDA phase III data some time in the early April; hence, it is very important to decide whether you want to take profits from here or continue to ride with the wave. Investing is all about risk management; and if you were to ask me if I am at all concerned that DCTH might pull another GNVC (Down more than -70% today), I sure am. And if I will be pissed if the results failed? I sure will. Will this completely decapitate my trading career? NOT A CHANCE because I have done my own due diligence and I know exactly how much I am risking. For one thing, this study is headed by the NCI (National Cancer Institute) and they have the most patients involved in this study, so everything seems very favorable for DCTH. There is always risk when it comes to investing, especially with biotech companies but I am willing to ride my core positions into FDA phase III data results.

Search This Blog